Annual Congress of the European Society for Medical Oncology (ESMO): Munich, Germany, 19–23 October 2018

Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer—the road to new treatment strategies. Lancet. 2017;389:2430–42. Robson M, Im SA, Senkus E, Xu B, Domcheck SM, Masuda N, et al. Olaparib for metastatic breast Cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–33. Litton JK, Tugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, et al. Talazoparib in patients with advanced breast Cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753–63. Clarke JM, George DJ, Lisi S, Salama AKS. Immune checkpoint blockade: the new frontier in Cancer treatment. Target Oncol. 2018;13(1):1–20. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast Cancer. N Engl J Med. 2018. https://doi.org/10.1056/NEJMoa1809615. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. IMpassion130: Results from a global, randomised, double-blind, phase 3 study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC). Ann Oncol. 2018;29(suppl_8) LBA1_PR. Vijayaraghavan S, Moulder S, Keyomarsi K, Layman RM. Inhibiting CDK in Cancer therapy: current evidence and future directions. Target Oncol. 2018;13:21–38. Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425–39. Pfizer Announces Overall Survival Results from Phase 3 PALOMA-3 Trial of IBRANCE® (Palbociclib) in HR+, HER2- Metastatic Breast Cancer. Press release 25 June 2018. https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_overall_survival_results_from_phase_3_paloma_3_trial_of_ibrance_palbociclib_in_hr_her2_metastatic_breast_cancer-0. Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, et al. Overall survival with Palbociclib and Fulvestrant in advanced breast Cancer. N Engl J Med. 2018 Oct 20. https://doi.org/10.1056/NEJMoa1810527. Cristofanilli M, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N. Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3. Ann Oncol. 2018;29(suppl_8) LBA2_PR. Araki K, Miyoshi Y. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer. 2018;25:392–401. Baselga J, Dent SF, Cortés J, Im YH, Diéras V, Harbeck N, et al. Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. J Clin Oncol. 2018;36(suppl_18) LBA1006. André F, Ciruelos EM, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the Phase 3 SOLAR-1 trial. Ann Oncol. 2018;29(suppl_8) LBA3_PR. Kumbla RA, Figlin RA, Posadas EM. Recent advances in the medical treatment of recurrent or metastatic renal cell Cancer. Drugs. 2017;77:17–28. Flippot R, Escudier B, Albiges L. Immune checkpoint inhibitors: toward new paradigms in renal cell carcinoma. Drugs. 2018;78:1443–57. Motzer RJ, Penkov K, Haanen JBAG, Rini BI, Albiges L, Campbell MT, et al. JAVELIN Renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). Ann Oncol. 2018;29(suppl_8) LBA6_PR. Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pfizer’s Inlyta® (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advanced or Metastatic Renal Cell Carcinoma. Press release 18 October 2018. https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-in-Combination-with-Pfizers-Inlyta-axitinib-Significantly-Improved-Overall-Survival-OS-and-Progression-free-Survival-PFS-as-First-Line-Therapy-for-Advanced-or-Metastatic-Renal-Cell-Carcinoma/default.aspx. O’Sullivan Coyne G, Chen AP, Meehan R, Doroshow JH. PARP inhibitors in reproductive system cancers: current use and developments. Drugs. 2017;77:113–30. Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Firedlander M, et al. Maintenance Olaparib in patients with newly diagnosed advanced ovarian Cancer. N Engl J Med October. 2018;21. https://doi.org/10.1056/NEJMoa1810858. Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Firedlander M, et al. Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial. Ann Oncol. 2018;29(suppl_8) LBA7_PR. Moreira J, Tobias A, O’Brien MP, Agulnik M. Targeted therapy in head and neck Cancer: an update on current clinical developments in epidermal growth factor receptor-targeted therapy and immunotherapies. Drugs. 2017;77:843–57. Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, De Castro G. KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Ann Oncol. 2018;29(suppl_8) LBA8_PR.